Voxelotor : A Hemoglobin S Polymerization Inhibitor for the Treatment of Sickle Cell Disease
© 2020 Harborside™..
Sickle cell disease (SCD) affects millions of people throughout the world. Hemoglobin S (HbS) polymerization is the fundamental cause of SCD pathophysiology, which leads to hemolysis, increased viscosity, and acute vaso-occlusive episodes. Novel agents have been developed to target the pathophysiology of SCD and decrease the frequency of SCD complications. Voxelotor (Oxbryta) is an HbS polymerization inhibitor that is approved by the U.S. Food & Drug Administration for the treatment of SCD in adults and pediatric patients 12 years and older.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:11 |
|---|---|
| Enthalten in: |
Journal of the advanced practitioner in oncology - 11(2020), 8 vom: 18. Nov., Seite 873-877 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Yenamandra, Avani [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Revised 10.11.2023 published: Print-Electronic Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.6004/jadpro.2020.11.8.7 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM320515311 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM320515311 | ||
| 003 | DE-627 | ||
| 005 | 20231225173740.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.6004/jadpro.2020.11.8.7 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1068.xml |
| 035 | |a (DE-627)NLM320515311 | ||
| 035 | |a (NLM)33489427 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Yenamandra, Avani |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Voxelotor |b A Hemoglobin S Polymerization Inhibitor for the Treatment of Sickle Cell Disease |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 10.11.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a © 2020 Harborside™. | ||
| 520 | |a Sickle cell disease (SCD) affects millions of people throughout the world. Hemoglobin S (HbS) polymerization is the fundamental cause of SCD pathophysiology, which leads to hemolysis, increased viscosity, and acute vaso-occlusive episodes. Novel agents have been developed to target the pathophysiology of SCD and decrease the frequency of SCD complications. Voxelotor (Oxbryta) is an HbS polymerization inhibitor that is approved by the U.S. Food & Drug Administration for the treatment of SCD in adults and pediatric patients 12 years and older | ||
| 650 | 4 | |a Journal Article | |
| 700 | 1 | |a Marjoncu, Dennis |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of the advanced practitioner in oncology |d 2012 |g 11(2020), 8 vom: 18. Nov., Seite 873-877 |w (DE-627)NLM235413690 |x 2150-0878 |7 nnns |
| 773 | 1 | 8 | |g volume:11 |g year:2020 |g number:8 |g day:18 |g month:11 |g pages:873-877 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.6004/jadpro.2020.11.8.7 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 11 |j 2020 |e 8 |b 18 |c 11 |h 873-877 | ||